Chromoanagenesis in Myelodysplastic Syndromes Is Associated With Highly Complex Karyotype, TP53 Disruption and Dismal Prognosis.
Optical genome mapping identifies a rare, ultra-high-risk subset of blood cancers with severe genetic chaos, enabling earlier recognition of patients needing urgent intervention.
Optical genome mapping in 332 MDS patients revealed chromoanagenesis (CAG) in 15.9% of cases, virtually all with TP53 multi-hit alterations and highly complex karyotypes, and a median overall survival of only 9.9 months versus not-reached in non-CAG cases. CAG-MDS represents a biologically distinct, ultra-high-risk subset with worse prognosis than even other very-high-risk IPSS-M categories, and OGM enables its efficient clinical detection.
What the study was
- Study design
- Retrospective cohort study with molecular analysis
- Population
- Patients with myelodysplastic syndromes (MDS), newly diagnosed and relapsed/refractory
- Sample size
- 332
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Modern Pathology
Why it surfaced
Large cohort (n=332) from MD Anderson by leading MDS experts (Medeiros, Garcia-Manero, Tang). Novel finding that CAG defines a biologically distinct ultra-high-risk MDS subset with ~3x worse prognosis than matched non-CAG very-high-risk patients. OGM enables efficient clinical detection. Score: novelty 3 (novel genomic entity, new prognostic stratification beyond IPSS-M), relevance 3 (directly impacts prognosis, treatment escalation, transplant decisions in MDS), design quality 1 (large retrospective cohort, no RCT), unmet need 1 (high-risk MDS has major unmet need but limited n in CAG group).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.